DIO Corporation (KOSDAQ:039840)
18,100
+600 (3.43%)
At close: Feb 6, 2026
DIO Corporation Revenue
DIO Corporation had revenue of 41.45B KRW in the quarter ending September 30, 2025, with 32.23% growth. This brings the company's revenue in the last twelve months to 155.15B, up 37.84% year-over-year. In the year 2024, DIO Corporation had annual revenue of 119.65B, down -23.21%.
Revenue (ttm)
155.15B
Revenue Growth
+37.84%
P/S Ratio
1.56
Revenue / Employee
323.91M
Employees
479
Market Cap
242.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% |
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% |
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% |
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% |
| Dec 31, 2020 | 120.06B | -7.11B | -5.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 3.90T |
| Chong Kun Dang Holdings | 950.10B |
| Suheung | 704.47B |
| Daewon Pharmaceutical | 590.70B |
| EASY BIO,Inc. | 465.24B |
| Ilyang Pharmaceutical Co.,Ltd | 276.09B |
| Samjin Pharmaceuticals | 274.03B |